<b>Introduction:</b>S100 calcium-binding protein B
(S100B) is a biochemical marker of astroglial
damage.
<br/><b>Purpose:</b> To assess the pathophysiological
implications of S100B concentrations in blood
plasma and cerebrospinal fluid of patients with
neurodegenerative central nervous system disorders.
<br/><b>Materials and Methods:</b> In this study, we
determined and compare S100B concentrations in
blood plasma and cerebrospinal fluid obtained from
subjects diagnosed with Alzheimer's disease (n=20),
amyotrophic lateral sclerosis (n=12), multiple
sclerosis (n=40) and the reference group (n=20),
using enzyme-linked immunosorbent assay.
<br/><b>Results:</b> Concentrations of S100B in plasma
collected from patients diagnosed with Alzheimer's
disease (252,38±183,50 pg/mL) and multiple
sclerosis (164,92±250,14 pg/mL) were above
laboratory standards, but in patients with
amyotrophic lateral sclerosis (53,96±56,92 pg/mL)
and the reference group (2,12 pg/mL) were below
laboratory norms (N>75 pg/mL). Concentrations of
S100B in plasma collected from patients with
Alzheimer's disease (252,38±183,50 pg/mL) were
significantly higher than in patients with
amyotrophic lateral sclerosis (53,96±56,92 pg/mL)
(p<0,029). Concentrations of S100B in CSF
collected from the reference group (546,96±236,62
pg/mL) and from patients with Alzheimer's disease
(587,53±189,57 pg/mL), amyotrophic lateral
sclerosis (404,41±179,56 pg/mL), multiple sclerosis
(462,03±146,01 pg/mL) were very similar, and none
of pairwise comparisons reached statistical
significance.
<br/><b>Conclusions:</b> Results of our studies indicate the
importance of S100B protein concentration
assessment in blood in central nervous system
disorders differential diagnostics.
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study